

January 2015

**ANNUAL DECLARATION OF INTERESTS
GLOBAL INITIATIVE FOR ASTHMA: SCIENCE COMMITTEE
1 January 2014 – December 2014**

GINA Committee members disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits*** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares*** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/dependent children < 18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests*** refers to fees or grants paid to a GINA Committee member (or the Department/Institution on behalf of a GINA member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$1,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the GINA Science Committee for the year 2014 is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Asthma (GINA)” on the website at: <<http://www.ginasthma.org>>.

SUMMARY FOR YEAR 2014:

Allan Becker, Winnipeg, Manitoba, Canada: *Personal Benefits* <\$10,000: AstraZeneca, Novartis, Sanofi. *Personal Benefits* >\$10,000: Merck Sharp & Dohme. *Shares*: none. *Non-Personal Interests* <\$10,000: Anaphylaxis Canada. *Personal Interests* >\$10,000: Allergen, CIHR.

Eric Bateman, Cape Town, South Africa: *Personal Benefits* \$10,000: Almirall, Cephalon, GlaxoSmithKline, Menarini, Pfizer, Peer Voice. *Personal Benefits* >\$10,000: AstraZeneca, Boehringer Ingelheim, ICON, Novartis, Takeda. *Shares*: none. *Non-Personal Interests*: none.

Johan de Jongste, Rotterdam, Netherlands: *Personal Benefits*: none. *Shares*: none. *Non-Personal Interests*: none.

Jeffrey M. Drazen, Boston Massachusetts US: *Personal Benefits*: none. *Shares*: none. *Non-Personal Interests*: none.

Mark FitzGerald, Vancouver, British Columbia, Canada: *Personal Benefits* <\$10,000: Aerocrine, AstraZeneca, Boehringer-Ingelheim, Merck Sharp & Dohme, Novartis, Roche. *Personal Benefits* >\$10,000: none. *Shares*: none. *Non-Personal Interests* >\$10,000: AllerGen NCE, Boehringer Ingelheim, Canadian Institute for Health Research, Genetech, GlaxoSmithKline, Medimmune, Novartis, Wyeth.

Hiromasa Inoue, Kogoshima Japan: *Personal Benefits <\$10,000:* Astellas, AstraZeneca, Chugai-Pharma, Eisai, GlaxoSmithKline, Kyoria, Merck Sharp & Dohme, MeijiSeikaPharma, Novartis, Otsuka, Pfizer, Teijin-Pharma. *Personal Benefits >\$10,000:* Boehringer-Ingelheim. *Shares:* none. *Non-Personal Interests <\$10,000:* Dainippon Sumitomo Pharma, Merck Sharp & Dohme, Teijin-Pharma. *Non-Personal Interests >\$10,000:* Astellas, Boehringer-Ingelheim, ChugaiPharma, Eisai, Pfizer.

Robert F. Lemanske, Jr., Madison, Wisconsin USA: *Personal Benefits <\$10,000:* none. *Shares:* none. *Non-Personal Benefits:* > \$10,000: Pharmaxis.

Paul O'Byrne, Hamilton, Ontario, Canada: *Personal Benefits <\$10,000:* AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Medimmune, Novartis, Verona. *Personal Benefits >\$10,000:* none. *Shares:* none. *Non-Personal Interests >\$10,000:* Ambit, Amgen, Novartis.

Soren Pedersen, Kolding, Denmark: *Personal Benefits <\$10,000:* Boehringer Ingelheim. *Personal Benefits >\$10,000:* GlaxoSmithKline. *Shares:* none. *Non-Personal Interests:* none

Emilio Pizzichini, Florianópolis – SC Brazil: *Personal Benefits <\$10,000:* Ache Lab (Br), AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Libbs Lab (Br), Merck Sharp & Dohme, Novartis. *Shares:* none. *Non-Personal Interests:* none.

Helen K. Reddel, Camperdown Australia: *Personal Benefits <\$10,000:* Boehringer-Ingelheim, Mundipharma, Merck Sharp & Dohme (DSMB), Teva. *Personal Benefits >\$10,000:* AstraZeneca (DSMB), GlaxoSmithKline (DSMB), Novartis (DSMB). *Shares:* none. *Non-Personal Interest >\$10,000:* AstraZeneca, GlaxoSmithKline.

Stanley J. Szeffler, Denver Colorado US: *Personal Benefits <\$10,000:* AstraZeneca, Boehringer-Ingelheim, Genentech, Merck Sharp & Dohme, Novartis, Roche. *Personal Benefits >\$10,000:* GlaxoSmithKline. *Shares:* none. *Non-Personal Interest >\$10,000:* GlaxoSmithKline.